BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CagriSema (cagrilintide/semaglutide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CagriSema (cagrilintide/semaglutide)\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07011667-121@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0701
 1667)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Obesity.\nStud
 y: A Research Study to Look at How Well CagriSema Helps People Living With
  Obesity Lose Weight and Maintain Weight Loss in the Long-term\nEstimated 
 primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cagrilintide-semaglutide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07011667
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817251-121@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0781
 7251)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Type 2 Diabete
 s.\nStudy: Research Study on How People With Type 2 Diabetes Tolerate Swit
 ching From Semaglutide to Cagrisema\nEstimated primary completion: 9 June 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide-se
 maglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07817251
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184086-121@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 1 readout est. (NCT0718
 4086)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 1\, Obesity.\nStud
 y: A Study to See How Metabolism is Influenced by Weight Loss Due to Inter
 vention With Cagrilintide and Semaglutide Compared to Diet\nEstimated prim
 ary completion: 12 October 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cagrilintide-semaglutide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07184086
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564414-121@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280223
DTEND;VALUE=DATE:20280224
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0756
 4414)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Obesity.\nStud
 y: A Research Study to Look at How Two Different Doses of CagriSema and On
 e Dose of Semaglutide Help People Living With Obesity With or Without Type
  2 Diabetes Lose Weight\nEstimated primary completion: 23 February 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide-semagluti
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7564414
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919405-121@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0791
 9405)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Obesity.\nStud
 y: A Research Study to Investigate How Well the Medicine CagriSema Lowers 
 High Blood Pressure in People Living With High Blood Pressure and Obesity\
 nEstimated primary completion: 1 June 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07919405
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282613-121@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0728
 2613)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Type 2 Diabete
 s.\nStudy: A Research Study to See How Much CagriSema Lowers Blood Sugar a
 nd Body Weight Compared to Placebo in Children and Adolescents With Type 2
  Diabetes\nEstimated primary completion: 7 September 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07282613
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
